Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

PROTEIN ALTERNATIVES SL

PROTEIN ALTERNATIVES SL_logo
18
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Biotechnology company focused on the design and development of biomarker-based assays for early diagnosis of cancer and novel monoclonal antibodies for targeted therapy in oncology

Tres Cantos, Madrid, Spain

Send a message

  • 10

    employees

  • €180,000

    turnover

Anglais

PROTEIN ALTERNATIVES SL

Anglais

Protein Alternatives (ProAlt) is a Spanish biotechnology company dedicated to the development of innovative, first-in-class therapeutic antibodies for the treatment of metastatic tumors and improved liquid phase diagnostic tools for the early detection of colorectal cancer. For the treatment of colorectal and melanoma metastatic tumors, the company has developed anti-cadherin 17 (CDH17) specific monoclonal antibodies. By targeting the conserved RGD...

See more

Protein Alternatives (ProAlt) is a Spanish biotechnology company dedicated to the development of innovative, first-in-class therapeutic antibodies for the treatment of metastatic tumors and improved liquid phase diagnostic tools for the early detection of colorectal cancer. For the treatment of colorectal and melanoma metastatic tumors, the company has developed anti-cadherin 17 (CDH17) specific monoclonal antibodies. By targeting the conserved RGD tripeptide domain in CDH17, the therapeutic mAb acts through a novel mode of action by inhibiting integrin beta 1 activation (mediated by RGD motif in cadherin 17), thus affecting cell adhesion, proliferation and migration. In vivo proof of concept studies with the humanized lead candidate PA-0661, using a murine model of metastatic disease, showed significant improvement in survival rates of all treated animals and avoided mestastasis formation in most of them. The company is seeking financing to complete during the next two years the preclinical development of the therapeutic monoclonal antibody PA-0661. The Company also considers to increase the investment series to include Phase I/IIa clinical trials in humans. 

  • 1

    Followers

  • 1

    Like

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1351 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1290 Members
Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
1931 Members